Full Breakdown
Fluvoxamine Shows Promise in Reducing Long COVID Fatigue
4/1/2026, 11:56:44 PM
Study Overview and Findings
A recent randomized clinical trial published in the *Annals of Internal Medicine* has found that fluvoxamine, a commonly prescribed antidepressant, significantly reduces fatigue in adults suffering from long COVID. The study, conducted by researchers from McMaster University and other institutions, involved 399 participants in Brazil who had experienced persistent fatigue for at least 90 days following a confirmed SARS-CoV-2 infection. Participants were randomly assigned to receive either fluvoxamine, metformin, or a placebo over a 60-day treatment period.
The results indicated that fluvoxamine led to a substantial reduction in fatigue severity, with a 99% probability that it outperformed the placebo. Improvements in quality of life were also reported, with sustained benefits observed even 30 days after treatment ended. In contrast, metformin, which has shown potential in preventing long COVID when taken during acute infection, did not demonstrate any meaningful benefits for established fatigue.
Background and Context
Long COVID, affecting an estimated 65 million people globally, is characterized by various debilitating symptoms, with fatigue being the most prevalent. Despite its widespread impact, effective treatments have been limited, often relegating care to supportive measures. The current study addresses a significant gap in treatment options for long COVID, particularly for fatigue, which has previously lacked targeted therapies.
Mechanism of Action
Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) known for its anti-inflammatory properties, which may contribute to its effectiveness in treating long COVID fatigue. It binds to the sigma-1 receptor, influencing immune regulation and cellular stress response, potentially alleviating symptoms associated with chronic inflammation. This unique profile distinguishes fluvoxamine from other SSRIs, making it a compelling candidate for addressing long COVID-related fatigue.
Official Statements & Responses
Edward Mills, senior author and professor at McMaster University, emphasized the significance of the findings, stating, “Fluvoxamine showed consistent and meaningful benefits, and because it's already widely used and well understood, it has clear potential for clinical use.” The researchers advocate for further studies to explore the drug's mechanisms and identify which patient subgroups may benefit most.
Criticism & Opposition
While the study's results are promising, some experts urge caution. Professor Christiaan Vinkers from the Amsterdam University Medical Centre noted that the trial's focus on fatigue did not encompass other long COVID symptoms, such as cognitive impairment or post-exertional malaise. Additionally, the study did not assess participants' histories of depression, raising questions about whether the observed effects were directly related to long COVID or underlying mental health issues.
Conflicting Reports & Gaps
Despite the encouraging results, the study's limitations include a lack of biological correlates to explain fluvoxamine's effects and the exclusion of certain patient demographics, such as those with pre-existing mental health conditions. These factors highlight the need for replication of the findings in broader populations and further investigation into the complex nature of long COVID.
What's Next
The researchers suggest that future trials should incorporate standardized assessments of depression and anxiety, alongside inflammatory and metabolic biomarkers, to clarify the mechanisms of fluvoxamine and its potential role in treating long COVID. As the medical community continues to grapple with the complexities of long COVID, fluvoxamine represents a significant step forward in developing evidence-based treatment options for affected individuals.
